Endometrial carcinoma (ECa) is one of the most common neoplasia of the female genital tract. The phosphatase and tensin (PTEN) homolog is the most frequently mutated tumor suppressor gene in endometrial carcinoma. PTEN encodes a phosphatase, a key regulatory enzyme involved in a signal transduction pathway that regulates cell growth, migration and apoptosis. The study evaluates an association between the morphological appearance of endometrial hyperplasia and ECa, and the presence of PTEN variations, PTEN protein´s level and intracellular localization. A total of 67 archived formalin-fixed and paraffin-embedded human biopsy tissue specimens with normal proliferative and secretory endometrium, endometrial hyperplasia without atypia and endometrial atypical hyperplasia, endometrioid the grade G1 and G3 and serous subtype of ECa were evaluated by sequencing for the presence of mutations in coding regions of PTEN gene of endometrial epithelial cells. The PTEN gene expression and intercellular localization of PTEN protein were evaluated immunohistochemically by immunoreactive score (IRS). PTEN mutation spectrum in endometrial carcinoma was identified for Slovak population. 28 non-silent mutations were identified in PTEN, twelve of them were novel, not annotated in Catalogue of Somatic Mutations in Cancer. Higher frequency of PTEN mutations was observed in serous carcinoma compared to global average. No correlation was observed between samples´ IRS, PTEN cellular localization and identified mutations. PTEN sequencing can be beneficial for patients considering prognosis of disease and sensitivity to treatment.

Institute of Medical Biology Genetics and Clinical Genetics Faculty of Medicine Comenius University in Bratislava University Hospital Bratislava Bratislava Slovak Republic

See more in PubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492. PubMed DOI

Diba CS, Pleško I, Hlava P. Incidencia zhubných nádorov v Slovenskej republike 2007. Bratislava: Národný onkologický register Slovenskej Republiky. National Health Information Centre; 2012. https://www.nczisk.sk .

Talhouk A, McAlpine JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract. 2016;3:14. doi: 10.1186/s40661-016-0035-4. PubMed DOI PMC

Silveberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA, Tavassoli FA. Epithelial tumors and related lesions. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. In: Tavassoli FA, Devilee P, editors. Tumours of the Uterine Corpus. World Heal. IARC Press; 2003. pp. 221–232.

Ellenson L, Matias-Guiu X, Mutter G. Editorial Board WC of TE, editor. Endometrial hyperplasia without atypia. In: Herrington CS, editor. WHO Classification of Tumours Female Genital Tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2020. pp. 248–249.

Kim K-R, Lax S, Lazar A, Longacre T, Malpica A, Matias-Guiu X, Nucci M, Oliva E. Editorial Board WC of T, editor. Endometrial epithelial tumours and precursors. In: Herrington CS, editor. WHO Classification of Tumours Female Genital Tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2020. pp. 248–267.

Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–17. doi: 10.1016/0090-8258(83)90111-7. PubMed DOI

Herrington CS Board WC of TE. Female Genital Tumours. International Agency for Research on Cancer; 2020.

Masood M, Singh N. Endometrial carcinoma: changes to classification (WHO 2020) Diagnostic Histopathol. 2021 doi: 10.1016/j.mpdhp.2021.09.003. DOI

Stavropoulos A, Varras M, Vasilakaki T, Varra VK, Tsavari A, Varra FN, Nonni A, Kavantzas N, Lazaris AC. Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression. Oncol Lett. 2019;17:4575–4589. doi: 10.3892/ol.2019.10093. PubMed DOI PMC

COSMIC – the Catalogue of Somatic Mutations in Cancer. The Sanger institute; [Accessed 27 October 2021]. https://cancer.sanger.ac.uk/cosmic/browse/tissue?wgs=off&sn=endometrium&ss=all&hn=carcinoma&sh=serous_carcinoma&in=t&src=tissue&all_data=n .

Halasova E, Adamkov M, Matakova T, Kavcova E, Poliacek I, Singliar A. Lung cancer incidence and survival in chromium exposed individuals with respect to expression of anti-apoptotic protein survivin and tumor suppressor P53 protein. Eur J Med Res. 2010;15:55. doi: 10.1186/2047-783X-15-S2-55. PubMed DOI PMC

Adamkov M, Halasova E, Kajo K, Machalekova K, Vybohova D, Varga I, Rajcany J. Survivin: A promising biomarker in breast carcinoma. Neoplasma. 2010;57:572–577. doi: 10.4149/neo_2010_06_572. PubMed DOI

Schultheis AM, Martelotto LG, De Filippo MR, Piscuoglio S, Ng CKY, Hussein YR, Reis-Filho JS, Soslow RA, Weigelt B. TP53 Mutational spectrum in endometrioid and serous endometrial cancers. Int J Gynecol Pathol. 2016;35:289. doi: 10.1097/PGP.0000000000000243. PubMed DOI PMC

Longy M. PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) [Accessed 27 October 2021]. http://atlasgeneticsoncology.org/Genes/PTENID158.html .

Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP. Crystal Structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 1999;99:323–334. doi: 10.1016/S0092-8674(00)81663-3. PubMed DOI

Chomanicova N, Gazova A, Adamickova A, Valaskova S, Kyselovic J. The role of AMPK/mTOR signaling pathway in anticancer activity of metformin. Physiol Res. 2021;70:501–508. doi: 10.33549/physiolres.934618. PubMed DOI PMC

Fan C, Zhao C, Shugen Li FW, Wang J. Significance of PTEN mutation in cellular process, prognosis, and drug selection in clear cell renal cell carcinoma. Front Oncol. 2019;9:357. doi: 10.3389/fonc.2019.00357. PubMed DOI PMC

Han F, Hu R, Yang H, Liu J, Sui J, Xiang X, Wang F, Chu L, Song S. PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis. Onco Targets Ther. 2016;9:3485–3492. doi: 10.2147/OTT.S99942. PubMed DOI PMC

Dillon LM, Miller TW. Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets. 2014;15:65. doi: 10.2174/1389450114666140106100909. PubMed DOI PMC

Li Y, Guessous F, Kwon S, Kumar M, Ibidapo O, Fuller L, Johnson E, Lal B, Hussaini I, Bao Y, Laterra J, Schiff D, et al. PTEN has tumor promoting properties in the setting of gain-of-function p53 mutations. Cancer Res. 2008;68:1723–1731. doi: 10.1158/0008-5472.CAN-07-1963. PubMed DOI PMC

Gbelcová H, Bakeš P, Priščáková P, Šišovský V, Hojsíková I, Straka L, Konečný M, Markus J, D’Acunto CW, Ruml T, Böhmer D, Danihel L, et al. PTEN sequence analysis in endometrial hyperplasia and endometrial carcinoma in Slovak women. Anal Cell Pathol. 2015;2015:746856. doi: 10.1155/2015/746856. PubMed DOI PMC

Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, De Placido G, Zullo F. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2018;231:104–110. doi: 10.1016/j.ejogrb.2018.10.025. PubMed DOI

Nero C, Ciccarone F, Pietragalla A, Scambia G. PTEN and gynecological cancers. Cancers (Basel) 2019;11:1458. doi: 10.3390/cancers11101458. PubMed DOI PMC

Cheung LWT, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Katherine SH, Dyer MD, Zhang F, Ju Z, Cantley LC, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011;1:170. doi: 10.1158/2159-8290.CD-11-0039. PubMed DOI PMC

Konopka B, Janiec-Jankowska A, Paszko Z, Goluda M. The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma. J Cancer Res Clin Oncol. 2003;130:114–121. doi: 10.1007/s00432-003-0518-7. PubMed DOI

Bononi A, Pinton P. Study of PTEN subcellular localization. Methods. 2015;77–78:92. doi: 10.1016/j.ymeth.2014.10.002. PubMed DOI PMC

Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, Gil E, Hinze R, Delbridge L, Lees JA, Mutter GL, Robinson BG, et al. Differential nuclear and cytoplasmic expression of PTEN in normalthyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol. 2000;156:1693. doi: 10.1016/S0002-9440(10)65040-7. PubMed DOI PMC

Gil A, Andrés-Pons A, Fernândez E, Valiente M, Torres J, Cervera J, Pulido R. Nuclear Localization of PTEN by a Ran-dependent mechanism enhances apoptosis: involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell. 2006;17:4002. doi: 10.1091/mbc.e06-05-0380. PubMed DOI PMC

Travaglino A, Raffone A, Saccone G, Mascolo M, Pignatiello S, Mollo A, De Placido G, Insabato L, Zullo F. PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer? APMIS. 2019;127:161–169. doi: 10.1111/apm.12938. PubMed DOI

Yang HP, Meeker A, Guido R, Gunter MJ, Huang GS, Luhn P, d’Ambrosio L, Wentzensen N, Sherman ME. PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors. Cancer Causes Control. 2015;26:1729. doi: 10.1007/s10552-015-0666-5. PubMed DOI PMC

Ørbo A, Arnes M, Lysa LM, Straume B. Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia. Anticancer Res. 2015;35:6401–6409. PubMed

Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 2002;277:5484–5489. doi: 10.1074/jbc.M108302200. PubMed DOI

Salvesen HB, Stefansson I, Kretzschmar EI, Gruber P, MacDonald ND, Ryan A, Jacobs IJ, Akslen LA, Das S. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol. 2004;25:1615–1623. doi: 10.3892/ijo.25.6.1615. PubMed DOI

Akiyama-Abe A, Minaguchi T, Nakamura Y, Michikami H, Shikama A, Nakao S, Sakurai M, Ochi H, Onuki M, Matsumoto K, Satoh T, Oki A, et al. Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas. Br J Cancer. 2013;109:1703–1710. doi: 10.1038/bjc.2013.455. PubMed DOI PMC

Zhang H, Wang S, Cacalano N, Zhu H, Liu Q, Xie M, Kamrava M, Konecny G, Jin S. Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines. Sci Reports. 2019;9:2111. doi: 10.1038/s41598-019-38585-9. PubMed DOI PMC

Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH, Yasmeen A. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer. 2017;17:638. doi: 10.1186/s12885-017-3639-0. PubMed DOI PMC

Bian X, Gao J, Luo F, Rui C, Zheng T, Wang D, Wang Y, Roberts TM, Liu P, Zhao JJ, Cheng H. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene. 2018;37:341–351. doi: 10.1038/onc.2017.326. PubMed DOI PMC